The U.S. Food and Drug Administration has approved the supplemental new drug application for Zoryve (roflumilast) cream 0.05% for the topical treatment of mild-to-moderate atopic dermatitis in children 2 to 5 years of age.
This article was originally published on MedicalXpress.com